Clinical trial
ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With…
NCT00040625 · Eli Lilly and Company, Industry · Approved for marketing
Key facts
| NCT number | NCT00040625 |
|---|---|
| Title | ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma. |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Approved for marketing |
| Study type | Expanded Access |
| Conditions | Mesothelioma |
| Intervention type | Drug |
| Interventions | Pemetrexed, Cisplatin |
| First posted | Jul 4, 2002 |
| Last update posted | Mar 15, 2007 |
| Countries | Brazil, Egypt, Saudi Arabia, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: